Post on 18-Mar-2018
transcript
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Technology Transfer from the Weizmann Institute of Science
f r o m o u r p i p e l i n e t o y o u r b o t t o m l i n e
Amir Naiberg, CEO
TTO Circle
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
The Weizmann Institute of Science Discovering Basic Science
Yeda R&D Co. Ltd. Bridging Research & Development
Past & Present Success Stories Anatomies of Success
Lessons learned
From Our Pipeline to Your Bottom Line
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
First Biotech Invention
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
And the Reward
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Imagine life without:
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Healing, Fueling, Feeding
Cherry Tomato Hybrids Sandisk Chip
Polymerico Fiber Optics
Mobileye Motorola Barcode Reader
Wheat Variants NDS Smart Card
HelioFocus
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Weizmann Institute of Science Curiosity Driven Research
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
What will be the next scientific revolution?
Who will make the next scientific revolution?
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
The next scientific revolution will be • driven by scientists who
have a multidisciplinary view of science
• the opportunity to take risks
• the infrastructure to work • the freedom to think
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
The Weizmann Institute of Science Focused on Research
400 administrative staff
10%
34%
40%
16%
260 professors Heading research groups
850 scientists Ph.D.’s, engineers & technicians
1,000 students M.Sc. and Ph.D. only
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
ERC Ranking
The highest success rate in the EU - close to 60% compared with 9% EU average
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Enhancing medical treatment efficacy using the most advanced research tools
The Israel National Center for Personalized Medicine
BENCH TO BEDSIDE
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
The Need to Re-think Innovation
Sources: InnoThink Center For Research In Biomedical Innovation; Thomson Reuters Fundamentals via FactSet Research Systems The Truly Staggering Cost Of Inventing New Drugs, Matthew Herper (Forbes, 10.2.2012)
Number of Drugs Approved
R&D Spending Per Drug ($Mil)
Total R&D Spending 1997-2011 ($Mil)
Company
5 11,790.93 58,955 AstraZeneca
10 8,170.81 81,708 GlaxoSmithKline
8 7,909.26 63,274 Sanofi
11 7,803.77 85,841 Roche Holding AG
14 7,727.03 108,178 Pfizer Inc.
15 5,885.65 88,285 Johnson & Johnson
11 4,577.04 50,347 Eli Lilly & Co.
8 4,496.21 35,970 Abbott Laboratories
16 4,209.99 67,360 Merck & Co Inc
11 4,152.26 45,675 Bristol-Myers Squibb Co.
21 3,983.13 83,646 Novartis AG
9 3,692.14 33,229 Amgen Inc.
139 5,773 802,468 Total
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
BIOTECHNOLOGY
Name of Drug/Company Indication 2012 ($ mil)
Enbrel (Amgen) and Humira (AbbVie) Rheumatoid Arthritis 17,850 Rebif (Merck Serono) Multiple Sclerosis 2,400 Erbitux (Bristol Myers and Eli Lilly) Colon cancer 1,800 Avonex (Biogen) Multiple Sclerosis 1,570 Gonal f (Merck Serono) Induction of ovulation 1,000 Remicade (Janssen Biotech) Rheumatoid Arthritis 970 Sub-Total 25,590
ISRAELI SCIENTIST ABROAD
Joseph Schlessinger - Sutent Kidney cancer 1,236
Aya Jakabovits - XGEVA/Prolia Osteoporosis in Postmenopausal Women 1,220
Aya Jakabovits - Vectibix Cancer of the Large Bowel 359 TOTAL 28,405
2012 Total Global Biopharmaceuticals Market 120,000 ISRAEL INSIDE Contribution (%) 24%
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Personalized Medicine – What is it?
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Sequencing Unit Building on the Weizmann Crown Human Genome Center, the unit will provide High Throughput DNA/RNA sequencing and affiliated bioinformatics to analyse genomic variations, transcriptomes, non-coding RNAs, and editomes.
The Israel National Center for Personalized Medicine Infrastructure
Proteomics Unit Arising from the Weizmann Advanced Mass Spectrometry Lab, the unit will provide quantitative proteomics analyses to study differential expression and post-translational modifications of proteins.
Bioinformatics Unit Build on the Bioinformatics and Biological Computing Group at Weizmann, the unit will use advanced tools to identify promising gene targets, key proteins and critical pathways.
Small Molecules Screening Unit Incorporating the Weizmann Structural Proteomics Unit for protein production and structure determination capacities, the unit will screen small molecule and siRNA libraries for desired biological effects.
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Yeda Research & Development Co. Ltd. Joint Development Process (e.g. Pharmaceutical)
Marketing of a New Drug
FDA Approvals
Clinical Studies
Pre Clinical Research
Basic Research
Innovation
Yeda’s Contribution
Building a Novel Eco System for collaborations
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Yeda Research & Development Co. Ltd. Bridging Research & Development
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
2003 2004 2005 2002 2006 2007 2008 2009 2010 2011 2012 4%
12%
20%
28%
36%
Glo
ba
l M
ark
et
Sh
are
(%
)
44%
52%
58%
66%
Sa
les ($
M)
0
400
800
1200
1600
2000
2400
2800
3300
4000
Yeda Research & Development Co. Ltd.
Source: Annual Companies reports for- Copaxone, Rebif & Avonex
37%
25%
Combining Benevolence & Business
Allow society to benefit from discoveries made at the Weizmann Institute of Science.
Effectively commercialize technologies developed at Weizmann to create additional income for the Institute.
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
* Source: AUTM Licensing Survey 2010
Licensing Income Survey 2010 top 10 Universities *
Institution Licensing Income ($M)
1 City of Hope National Medical Center. & Beckman Research
202
2 Northwestern Univ. 179
3 NYU 178
4 Columbia Univ. 147
5 Sloan Kettering Inst. For Cancer Res. 139
6 Univ. California System 104
7 Wake Forest Univ. 85
8 Univ. of Minnesota 83
9 The General Hospital dba Massachusetts General Hos.
77
10 Univ. of Washington 69
Yeda Research & Development Co. Ltd. Licensing Income
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
403
325
164 144 141
95 90 87 77 77 63 62 61 61 57 57
0
50
100
150
200
250
300
350
400
450
Source: BDI
Israeli Patents in the USA (Accumulated for the Years 2006-2010)
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Yeda Research & Development Co. Ltd. Technologies Portfolio
Biotehnology, 57%
Physics, 7%
Medical devices, 7%
Mathematics, 7%
Chemistry, 11%
Agriculture, 5%
Environmental, 5%
Bioinformatics, 1%
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Yeda Research & Development Co. Ltd. Favorable Environmental Conditions
Legal structure similar to Bayh-Dole act
IP owned by the Institution
Sharing royalty with the inventors
Government support programs
Incubators
Direct tech transfer support programs
Developed investors community, Entrepreneurs
However, a funding gap for series A round
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Yeda Research & Development Co. Ltd. Favorable Internal Conditions
Scientists’ focus on excellence in Basic Science.
A pro-active tech transfer operation: Looking inward for technologies, outward for licensees.
Tech Transfer officers with combined background in both Science & Business.
Resources & willingness to further assess and develop technologies prior to licensing.
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Yeda Research & Development Co. Ltd. A World Leader in Technology Transfer
Dozens of “Weizmann-Inside” products on the market.
Total annual royalty-generating sales in 2012: Over $17 Billion.
Over 70 new companies were established around Yeda’s technologies.
Yeda owns the largest portfolio of patents in Israel: 550 live patent families, with more than 1,700 patent families filed since 1971.
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Yeda / Weizmann Success Stories Anatomies of Success
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Yeda / Weizmann Success Stories Selected Success Stories
ErbituxTM | ImClone
QX Capsule | QuantomiXTM
Yeda / Weizmann Success Stories
Copaxone® | Teva
Rebif
® | Merck Serono
Encryption Algorithm | NDS
GeneCardsTM | XenneX
NanoLubTM | Nanomaterials
Dunaliella | Nikken Sohonsha
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Personalized Technology Transfer!
The Right Agreement for each Technology
Think and Act Globally
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Some Issues
Invention disclosures are made locally but will be examined on a country by country basis.
How do we deal with the reporting requirements under the Bayah Dole Act?
What are the requirements of the local R&D encouragement laws?
Patent Law
USA finally moving to first to file
Where to enforce?
Joint owners
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Cont’d.
Laws relating to import and export:
Limitation on export and import
Antitrust law (grant back, royalty term)
EU Technology Transfer Block Exemption
Antitrust Guidelines for the Licensing of Intellectual Property
Laws relating to Pre-Clinical, Clinical trails and other regulatory agencies.
Tax issues such as withholding tax.
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Non-exclusive license is suitable in cases where the technology is relatively matured and could be used as a research tool or becomes an industry standard.
Points to consider:
Choice of law and forum
Improvements
Most Favored Nation Clause
It gets really complicated with non-exclusive deals
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
Israeli Model
Sublicensing
Assignment
M&A
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. Yeda R&D Co. Ltd, Nanjing IP Seminar Adv. Galit Yosha March 22-23, 2012
38
(Bismark)
Murphy’s law:
Technology Transfer from the Weizmann Institute of Science
Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m
www. YedaRnD. c o m T h a n k y o u